Stockreport

Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."

DSS, Inc.  (DSS) 
NASDAQ:AMEX Investor Relations: dsssecure.com
PDF NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce [Read more]